Your browser doesn't support javascript.
loading
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
Magbanua, Mark Jesus M; Hendrix, Laura H; Hyslop, Terry; Barry, William T; Winer, Eric P; Hudis, Clifford; Toppmeyer, Deborah; Carey, Lisa Anne; Partridge, Ann H; Pierga, Jean-Yves; Fehm, Tanja; Vidal-Martínez, José; Mavroudis, Dimitrios; Garcia-Saenz, Jose A; Stebbing, Justin; Gazzaniga, Paola; Manso, Luis; Zamarchi, Rita; Antelo, María Luisa; Mattos-Arruda, Leticia De; Generali, Daniele; Caldas, Carlos; Munzone, Elisabetta; Dirix, Luc; Delson, Amy L; Burstein, Harold J; Qadir, Misbah; Ma, Cynthia; Scott, Janet H; Bidard, François-Clément; Park, John W; Rugo, Hope S.
Afiliação
  • Magbanua MJM; Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Hendrix LH; Duke Cancer Institute, Duke University, Durham, NC, USA.
  • Hyslop T; Duke Cancer Institute, Duke University, Durham, NC, USA.
  • Barry WT; Alliance Statistics and Data Center, Dana-Farber/Partners CancerCare, Boston, MA, USA.
  • Winer EP; Rho Inc., Raleigh, NC, USA.
  • Hudis C; Dana-Farber/Partners CancerCare, Boston, MA, USA.
  • Toppmeyer D; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Carey LA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Partridge AH; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
  • Pierga JY; Dana-Farber/Partners CancerCare, Boston, MA, USA.
  • Fehm T; Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France.
  • Vidal-Martínez J; Department of Gynecology and Obstetrics, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Mavroudis D; Clinical Laboratory, Hospital Arnau de Vilanova, Valencia, Spain.
  • Garcia-Saenz JA; Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece.
  • Stebbing J; Department of Medical Oncology, University Hospital of Heraklion, Greece.
  • Gazzaniga P; DCIBERONC, IdISCC Madrid, Spain.
  • Manso L; Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK.
  • Zamarchi R; Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
  • Antelo ML; Hospital 12 de Octubre, Madrid, Spain.
  • Mattos-Arruda L; Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Generali D; Department of Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Caldas C; Val d'Hebron Institute of Oncology, Val d'Hebron University Hospital, and Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Munzone E; Women Cancer Center, University of Trieste, Trieste, Italy.
  • Dirix L; Cancer Research UK Cambridge Institute and Department of Oncology Li Ka Shing Centre, University of Cambridge, Cambridge, UK.
  • Delson AL; Division of Medical Senology, European Institute of Oncology, IRCCS, Milano, Italy.
  • Burstein HJ; Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Antwerp, Belgium.
  • Qadir M; University of Antwerp, Antwerp, Belgium.
  • Ma C; Breast Science Advocacy Group, University of California San Francisco, San Francisco, CA, USA.
  • Scott JH; Dana-Farber/Partners CancerCare, Boston, MA, USA.
  • Bidard FC; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
  • Park JW; Washington University School of Medicine, St. Louis, MO, USA.
  • Rugo HS; Division of Hematology Oncology, University of California San Francisco, San Francisco, CA, USA.
J Natl Cancer Inst ; 113(4): 443-452, 2021 04 06.
Article em En | MEDLINE | ID: mdl-32770247
ABSTRACT

BACKGROUND:

We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy.

METHODS:

Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS.

RESULTS:

Latent mixture modeling revealed 4 distinct tCTC patterns undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model.

CONCLUSIONS:

We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Células Neoplásicas Circulantes Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Células Neoplásicas Circulantes Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2021 Tipo de documento: Article